Equities analysts predict that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will report $10.20 million in sales for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have made estimates for Ultragenyx Pharmaceutical’s earnings, with estimates ranging from $4.91 million to $18.92 million. Ultragenyx Pharmaceutical reported sales of $200,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 5,000%. The company is expected to issue its next earnings report on Thursday, November 1st.
According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year sales of $46.49 million for the current year, with estimates ranging from $25.22 million to $72.18 million. For the next financial year, analysts forecast that the company will report sales of $99.94 million, with estimates ranging from $74.10 million to $143.68 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.08) by $1.02. Ultragenyx Pharmaceutical had a negative return on equity of 44.09% and a negative net margin of 703.27%. The firm had revenue of $12.79 million for the quarter, compared to analysts’ expectations of $5.63 million. During the same period last year, the firm earned ($1.72) EPS.
Shares of Ultragenyx Pharmaceutical stock opened at $63.28 on Friday. Ultragenyx Pharmaceutical has a twelve month low of $41.67 and a twelve month high of $90.98. The stock has a market capitalization of $3.31 billion, a P/E ratio of -8.44 and a beta of 1.95.
In other news, CFO Shalini Sharp sold 6,700 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $90.07, for a total value of $603,469.00. Following the transaction, the chief financial officer now directly owns 56,828 shares of the company’s stock, valued at $5,118,497.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director William Aliski sold 3,750 shares of the business’s stock in a transaction that occurred on Wednesday, August 8th. The shares were sold at an average price of $76.66, for a total transaction of $287,475.00. Following the transaction, the director now directly owns 72,610 shares in the company, valued at $5,566,282.60. The disclosure for this sale can be found here. Insiders have sold a total of 35,000 shares of company stock worth $2,700,774 over the last 90 days. 8.40% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 3.8% in the second quarter. BlackRock Inc. now owns 4,389,350 shares of the biopharmaceutical company’s stock worth $337,408,000 after buying an additional 158,723 shares during the last quarter. Federated Investors Inc. PA grew its holdings in shares of Ultragenyx Pharmaceutical by 18.2% in the 2nd quarter. Federated Investors Inc. PA now owns 1,417,551 shares of the biopharmaceutical company’s stock worth $108,967,000 after purchasing an additional 218,060 shares during the last quarter. First Trust Advisors LP grew its holdings in shares of Ultragenyx Pharmaceutical by 1.7% in the 2nd quarter. First Trust Advisors LP now owns 977,505 shares of the biopharmaceutical company’s stock worth $75,141,000 after purchasing an additional 16,713 shares during the last quarter. Northern Trust Corp lifted its position in Ultragenyx Pharmaceutical by 6.7% during the 2nd quarter. Northern Trust Corp now owns 554,092 shares of the biopharmaceutical company’s stock worth $42,594,000 after buying an additional 34,942 shares in the last quarter. Finally, Voya Investment Management LLC lifted its position in Ultragenyx Pharmaceutical by 2,221.4% during the 2nd quarter. Voya Investment Management LLC now owns 426,788 shares of the biopharmaceutical company’s stock worth $32,807,000 after buying an additional 408,403 shares in the last quarter. Hedge funds and other institutional investors own 96.11% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Read More: Rule of 72
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.